Oragenics Selects Southern Star Research As Clinical Research Organization for ONP-002 Phase IIa Trial

Strategic CRO Partnership Supports Operational Readiness and Initiation of Upcoming Concussion Study

UF Innovate | Accelerate graduate Oragenics, Inc., a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for concussion.

Southern Star Research is a globally recognized, full-service CRO with a proven track record in delivering early-phase trials across Australia and Asia-Pacific. Their deep operational expertise, regulatory knowledge, and hands-on site management capabilities will support the execution of Oragenics’ randomized, double-blind, placebo-controlled Phase IIa study evaluating ONP-002 in adults with mild traumatic brain injury (mTBI).

Read more about Oragenics Selects Southern Star Research As Clinical Research Organization for ONP-002 Phase IIa Trial.